Amgen (AMGN): FY24 Q4 earnings call, Feb 4, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 4, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Acquisition”; 4 quoted, at least 25 words apart.
…previously announced $500 million in pretax cost synergies by year 3 post acquisition. The acquisition was accretive to non-GAAP EPS for the full year 2024.…
…is Amgen's stance on looking overseas for clinical-stage assets? And I guess more broadly, what is your appetite for M&A now post the Horizon acquisition?
…and maintained a very active search for interesting opportunities for licensing and acquisitions all around the globe. And yes, we're open for business, looking for…
…overall brand. And it's obviously one of the things that drove the acquisition, the ability for Amgen's global footprint to bring these medicines to more…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-02-04:earnings_call · words: /api/v1/brief?appearance=amgen:2025-02-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP